Brensocatib is under clinical development by Insmed and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Brensocatib’s likelihood of approval (LoA) and phase transition for Hidradenitis Suppurativa took place on 25 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 25 Oct 2022 increased Brensocatib’s LoA and PTSR for Rhinosinusitis.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Brensocatib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Brensocatib overview

Brensocatib (INS-1007, AZD-7986) is under development for the treatment of neutrophil mediated diseases including non-cystic fibrosis bronchiectasis, cystic fibrosis, chronic obstructive pulmonary fibrosis (COPD), coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hidradenitis suppurativa and chronic rhinosinusitis without nasal polyps. The drug candidate is administered through oral route. It acts by targeting dipeptidyl peptidase 1 (DPP1). 

It was also under development for granulomatosis with polyangiitis.

Insmed overview

Insmed is a biopharmaceutical company that focuses on developing novel therapeutics for rare diseases. Its marketed product, Arikayce (liposomal amikacin for inhalation) is indicated for mycobacterium avium complex (MAC) lung infection and NTM lung infections caused by MAC in adult patients. The company uses its proprietary, liposomal technology to develop its novel drug candidates. Its pipeline products include brensocatib for non-cystic fibrosis (non-CF) bronchiectasis, cystic fibrosis and COVID-19; TPIP, an inhaled formulation of a treprostinil prodrug for pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis, and PAH associated with interstitial lung diseases. The company operates in the US, the UK, the Netherlands, Ireland, Italy, Germany, France and Japan through its subsidiaries. Insmed is headquartered in Bridgewater, New Jersey, the US.

Quick View Brensocatib LOA Data

Report Segments
  • Innovator
Drug Name
  • Brensocatib
Administration Pathway
  • Oral
Therapeutic Areas
  • Dermatology
  • Ear Nose Throat Disorders
  • Immunology
  • Infectious Disease
  • Respiratory
Key Developers
  • Sponsor Company: Insmed
  • Originator: AstraZeneca
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.